Glaucoma steals sight slowly and silently, and for millions of patients the daily ritual of medicated eyedrops has long been the price of holding on to their vision. Now a real-world study published in the journal Advances in Therapy suggests that a tiny, drug-eluting implant placed inside the eye during a short surgical procedure can meaningfully lower intraocular pressure while cutting dependence on topical medications by more than half — and that pairing the implant with other minimally invasive glaucoma procedures may deliver an even greater reduction in the burden of daily drops.
The study, conducted by ophthalmologist Arkadiy Yadgarov of Omni Eye Atlanta, examined 85 eyes with primary open-angle glaucoma, the most common form of the disease, that received the travoprost intracameral implant known commercially as iDose TR. The device is a titanium implant measuring just 1.8 by 0.5 millimeters, preloaded on a sterile single-use inserter and anchored into the sclera at the iridocorneal angle through a clear corneal incision. Once seated in the trabecular meshwork, it elutes a steady supply of travoprost, a prostaglandin analogue that enhances uveoscleral outflow of aqueous humor, the fluid whose accumulation drives dangerous pressure inside the eye.
What makes the implant conceptually powerful is that it decouples drug delivery from patient behavior. Decades of research have shown that chronic eyedrop therapy is undermined by nonadherence, with many patients missing doses or abandoning regimens entirely, and by the ocular surface disease caused by preservatives and active ingredients in the drops themselves. Fluctuating intraocular pressure between doses contributes to disease progression, and the American Academy of Ophthalmology has recently acknowledged medication reduction as a treatment endpoint comparable in importance to pressure reduction when judging surgical success. Procedural pharmaceuticals like iDose TR and its bimatoprost counterpart Durysta are designed to sidestep these failures entirely by providing consistent, sustained elution regardless of whether a patient remembers to instill a drop.
In the new study, the implant was used as a standalone procedure in 40 eyes and combined with minimally invasive glaucoma surgery, or MIGS, in 45 eyes. The combined cases most frequently paired iDose TR with the iStent infinite, a third-generation trabecular microbypass stent that enhances outflow through the conventional trabecular pathway — a complementary mechanism to the uveoscleral outflow boosted by travoprost. Sixteen eyes received the implant, the stent, and phacoemulsification cataract surgery together, while seven eyes received the implant with other MIGS procedures, with or without cataract surgery. The surgeon’s rationale was straightforward: combining modalities that act on different outflow pathways might achieve additive pressure control and a deeper reduction in medication dependence than either approach alone.
The results were striking across the board. Mean intraocular pressure fell from 17.2 millimeters of mercury at baseline to 14.5 millimeters at three months, a reduction of 2.7 millimeters of mercury, or 15.7 percent, with a p value below 0.001. Mean medication burden dropped from 1.9 medications per eye to 0.9, a 52.6 percent reduction. The proportion of eyes achieving pressures of 18 millimeters of mercury or lower rose from 63.5 percent to 81.2 percent, and the proportion reaching 12 millimeters or lower — a threshold often required in more advanced disease — nearly doubled from 17.6 percent to 40 percent. Most dramatically, the fraction of eyes completely free of eyedrops jumped from 7.1 percent before surgery to 47.1 percent at three months, meaning 40 percent of eyes that had been on medications at baseline became medication-free.
Subgroup analyses added an important layer to the findings. Pressure and medication reductions were statistically significant in every subgroup examined, whether stratified by disease severity, by surgical category, or by race and ethnicity, and there were no significant between-subgroup differences in pressure outcomes. Notably, the cohort included 29.4 percent Black patients, a group historically underrepresented in glaucoma device trials despite carrying an elevated risk of disease progression and surgical failure. The absence of any detectable difference in outcomes between White and Black patients in this series offers preliminary reassurance that the technology performs consistently across a diverse real-world population, though the authors caution that the subgroups were small and unmatched.
The one statistically significant between-group difference emerged in the surgical category comparison: combined procedures produced significantly greater medication reduction than standalone implantation. Eyes receiving iDose TR plus iStent infinite reduced their medication count by 1.2 from a baseline of 2.4, while eyes receiving the implant, stent, and phacoemulsification together achieved a reduction of 1.4 from a baseline of 1.7. Standalone implantation, by contrast, reduced medications by 0.8 from a baseline of 1.6. The investigators attribute this additive effect to the simultaneous enhancement of two distinct aqueous outflow mechanisms — uveoscleral outflow from the travoprost implant and trabecular outflow from the microbypass stent — with the continuous, stable drug elution potentially outperforming topical drops by circumventing the peak-and-trough pharmacokinetics of eyedrop dosing.
Safety results were equally encouraging. There were no intraoperative complications in any of the 85 eyes, and only two postoperative adverse events were recorded, each affecting a single eye. One eye experienced a pressure spike of at least 10 millimeters of mercury above baseline at one month, which occurred after the patient was inadvertently advised to stop all eyedrops; restarting the previous medication brought the pressure down to 10 millimeters of mercury by three months. The other event was a branch retinal vein occlusion in a patient with severe glaucoma, systemic hypertension, and a history of three prior glaucoma procedures, managed with an intravitreal anti-VEGF injection after retina consultation. No severe or sight-threatening complications occurred, no device dislodgement or explantation was needed, and no secondary glaucoma interventions were required during the follow-up period.
The comparatively modest pressure reduction in this study, relative to the 5.5 to 8.5 millimeter reductions reported in iDose TR’s pivotal clinical trials, reflects a fundamental difference in the patient population rather than a failure of the device. Clinical trials typically wash patients off medications before measuring baseline pressure, yielding starting pressures of 24 to 25 millimeters of mercury, whereas this real-world cohort began at a medicated average of 17.2 millimeters. Because higher starting pressures leave more room for improvement, the smaller absolute reduction here is expected. The cohort also included 35 percent severe glaucoma — a group excluded from the pivotal trials — and medications were titrated more cautiously in these advanced eyes, which may have tempered the medication reduction as well.
The study’s limitations are real and worth weighing: it was retrospective, nonrandomized, single-center, and followed patients for only three months, and the subgroup analyses should be treated as exploratory until validated in larger, matched cohorts. Still, the message for patients and clinicians is compelling. A procedure lasting minutes, performed through a microscopic incision, can deliver months of continuous glaucoma medication from a device the size of a grain of rice, and when layered with a trabecular stent it can free nearly half of patients from eyedrops altogether. As the field pivots toward what its proponents call interventional glaucoma — treating the disease earlier and more decisively with procedural tools rather than relying on lifelong drop adherence — this study provides some of the strongest real-world evidence yet that multimodal, multimechanism therapy can deliver on that promise safely.
Subject of Research: Real-world outcomes of the travoprost intracameral implant used alone or combined with minimally invasive glaucoma surgery
Article Title: Travoprost Intracameral Implant as a Standalone Procedure or Combined with Minimally Invasive Glaucoma Surgery (MIGS)
Article References: Yadgarov, A. (2026). Travoprost Intracameral Implant as a Standalone Procedure or Combined with Minimally Invasive Glaucoma Surgery (MIGS). Advances in Therapy. https://doi.org/10.1007/s12325-026-03778-y
Image Credits: AI Generated
DOI: 10.1007/s12325-026-03778-y
Keywords: glaucoma, iDose TR, travoprost implant, MIGS, intraocular pressure, iStent infinite, procedural pharmaceuticals, ophthalmology, medication adherence, interventional glaucoma, phacoemulsification, primary open-angle glaucoma
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (October 2, 2026). Tiny Eye Implant Slashes Glaucoma Drops by Half in Real-World Study. Scienmag. https://scienmag.com/tiny-eye-implant-slashes-glaucoma-drops-by-half-in-real-world-study/
Ophelia Keating. “Tiny Eye Implant Slashes Glaucoma Drops by Half in Real-World Study.” Scienmag, 2 October 2026, https://scienmag.com/tiny-eye-implant-slashes-glaucoma-drops-by-half-in-real-world-study/. Accessed 2 October 2026.
Ophelia Keating. “Tiny Eye Implant Slashes Glaucoma Drops by Half in Real-World Study.” Scienmag. October 2, 2026. https://scienmag.com/tiny-eye-implant-slashes-glaucoma-drops-by-half-in-real-world-study/
Copy citation Download RIS
Tags: drug-eluting eye implanteye drop dependencyglaucomaglaucoma management innovationsGlaucoma treatmentiDose TRinnovative glaucoma therapiesinterventional glaucomaintracameral implantintraocular pressureintraocular pressure reductioniStent infinitemedication adherenceMIGSminimally invasive glaucoma surgeryocular drug deliveryophthalmic surgical proceduresophthalmologyphacoemulsificationprimary open-angle glaucomaprocedural pharmaceuticalstravoprost implant
